These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8116055)

  • 1. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443).
    Laskow DA; Deierhoi MH; Hudson SL; Orr CL; Curtis JJ; Diethelm AG
    Transplantation; 1994 Feb; 57(4):640-3. PubMed ID: 8116055
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group.
    Woodle ES; Jordan ML; Facklam D; Shapiro R; Danovitch GM
    Transplant Proc; 1998 Jun; 30(4):1297-8. PubMed ID: 9636526
    [No Abstract]   [Full Text] [Related]  

  • 3. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation.
    Deierhoi MH; Sollinger HW; Diethelm AG; Belzer FO; Kauffman RS
    Transplant Proc; 1993 Feb; 25(1 Pt 1):693-4. PubMed ID: 8438440
    [No Abstract]   [Full Text] [Related]  

  • 4. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan.
    Takahashi K; Ochiai T; Uchida K; Yasumura T; Ishibashi M; Suzuki S; Otsubo O; Isono K; Takagi H; Oka T
    Transplant Proc; 1995 Feb; 27(1):1421-4. PubMed ID: 7878933
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycophenolate mofetil reduces graft loss due to chronic allograft nephropaty.
    Falkiewicz K; Kuriata M; Boratyńska M; Klinger M; Szepietowski T; Patrzałek D; Szyber P
    Transplant Proc; 2002 Mar; 34(2):567-8. PubMed ID: 12009626
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycophenolate-update after it has come of age.
    Grinyó JM
    Nephrol Dial Transplant; 1999 Jan; 14(1):31-4. PubMed ID: 10052471
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytokine analysis before and after mycophenolate mofetil treatment in renal transplantation.
    Oliveira JG; Sampaio S; Xavier P; Aragão P; Mendes A; Guerra L
    Transplant Proc; 2000 Dec; 32(8):2631-2. PubMed ID: 11134732
    [No Abstract]   [Full Text] [Related]  

  • 8. Mycophenolate mofetil in the treatment of chronic rejection in renal transplantation: 3-year follow-up.
    Noronha IL; Oliveira AC; Abensur H; Romão JE; Araújo MR; Zatz R
    Transplant Proc; 2002 Mar; 34(2):491-3. PubMed ID: 12009601
    [No Abstract]   [Full Text] [Related]  

  • 9. Mycophenolate mofetil to rescue children with acute renal transplant rejection.
    Birkeland SA
    Lancet; 1996 Jun; 347(9016):1699-700. PubMed ID: 8642993
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic interaction between sodium valproate and mycophenolate in renal allograft recipients.
    Annapandian VM; John GT; Mathew BS; Fleming DH
    Transplantation; 2009 Nov; 88(9):1143-5. PubMed ID: 19898213
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of mycophenolate mofetil (Cellcept) in renal transplantation.
    Vanrenterghem Y
    Contrib Nephrol; 1998; 124():64-9; discussion 69-75. PubMed ID: 9761975
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycophenolate mofetil.
    Bell J; Ross K
    ANNA J; 1996 Aug; 23(4):409-10, 413. PubMed ID: 8900688
    [No Abstract]   [Full Text] [Related]  

  • 13. RS-61443 reverses acute renal allograft rejection in dogs.
    Platz KP; Bechstein WO; Eckhoff DE; Hullett DA; Sollinger HW
    Transpl Int; 1992; 5 Suppl 1():S542-3. PubMed ID: 14621871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic monitoring of mycophenolate mofetil.
    Jeong H; Kaplan B
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):184-91. PubMed ID: 17699403
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of acute humoral rejection in liver transplantation: successful treatment with plasmapheresis and mycophenolate mofetil.
    Rostron A; Carter V; Mutunga M; Cavanagh G; O'Suilleabhain C; Burt A; Jaques B; Talbot D; Manas D
    Transpl Int; 2005 Nov; 18(11):1298-301. PubMed ID: 16221162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of acute allograft rejection using immunotoxin.
    Knechtle SJ; Fechner JH; Stavrou S; Neville DM; Dong Y; Hong X; Tsuchida M; Hamawy MM
    Transplant Proc; 1998 Aug; 30(5):2150-1. PubMed ID: 9723422
    [No Abstract]   [Full Text] [Related]  

  • 17. Mycophenolate mofetil (CellCept): immunosuppression on the cutting edge.
    Siconolfi L
    AACN Clin Issues; 1996 Aug; 7(3):390-402. PubMed ID: 8826401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients.
    Budde K; Glander P; Braun KP; Böhler T; Waiser J; Fritsche L; Mai I; Neumayer H
    Transplant Proc; 2001; 33(7-8):3313-5. PubMed ID: 11750418
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute rejection and renal allograft outcome.
    Vanrenterghem YF
    Nephrol Dial Transplant; 1995; 10 Suppl 1():29-31. PubMed ID: 7617277
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil aggravates postischemic acute renal failure in rats.
    González N; Alvarez V; Pons H; Parra G; Quiroz Y; Rodríguez-Iturbe B
    Transplant Proc; 2002 Feb; 34(1):43-4. PubMed ID: 11959177
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.